|
|
Article: Biocon and Abraxis BioScience Launch ABRAXANE in India for Treatment of Breast Cancer.
- Article from:
- Business Wire
- Article date:
- July 18, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BANGALORE, India, & LOS ANGELES -- Biocon Limited, India's pioneering biotechnology company, and Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, today announced the launch of ABRAXANE([R]) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in India for the treatment of breast cancer after failure of combination therapy for metastatic disease or relapse within six months of adjuvant chemotherapy. ABRAXANE is now available in India as a single-use 100 mg vial (as a lyophilized powder, to be reconstituted for intravenous administration).
In October 2007, ABRAXANE was approved by the Drug Controller ...